NEW YORK/TOKYO — Pharmaceutical products forced into forced labor in China's Xinjiang region are headed for Japan and the United States.
Japan's Pharmaceuticals and Medical Devices Agency (PMDA) and the US Food and Drug Administration are granting licenses to two drugmakers linked to Xinjiang, according to a report published Tuesday by global security nonprofit C4ADS.